Drs. Joshua Brody and Jeremy Abramson weigh in on SOHO Spotlight.
🎧 soho.click/soho-spotlig... #DLBCL #HemOnc
Drs. Joshua Brody and Jeremy Abramson weigh in on SOHO Spotlight.
🎧 soho.click/soho-spotlig... #DLBCL #HemOnc
#Oncology #ClinicalTrials
https://thepriorityreview.com/news/epcoritamab-china-dlbcl-median-overall-survival-7-7-vs-9-0-months
#Oncology #ClinicalTrials
https://thepriorityreview.com/news/epcoritamab-china-dlbcl-median-overall-survival-7-7-vs-9-0-months
Read more here 📰: www.onclive.com/view/rocbrut...
#oncology #lymsm
Read more here 📰: www.onclive.com/view/rocbrut...
#oncology #lymsm
*1st results of Iomab-ACT as conditioning in SCD
*Low dose Iomab-ACT for r/r DLBCL & B-cell ALL
*Iomab-ACT conditioning before CD19-directed CAR T-cell therapy
#$ATNM
ir.actiniumpharma.com/press-releas...
*1st results of Iomab-ACT as conditioning in SCD
*Low dose Iomab-ACT for r/r DLBCL & B-cell ALL
*Iomab-ACT conditioning before CD19-directed CAR T-cell therapy
#$ATNM
ir.actiniumpharma.com/press-releas...
Bjoern Chapuy on elderly patients: first, do no harm.
Maria Gomes da Silva on first line DLBCL, including pitfalls like CNS prophylaxis and double-hit lymphoma. 🧵
#ESHLYMPHOMA2026 #ESHCONFERENCES #LYMsm #Lmsm #ESHELEARNING
Bjoern Chapuy on elderly patients: first, do no harm.
Maria Gomes da Silva on first line DLBCL, including pitfalls like CNS prophylaxis and double-hit lymphoma. 🧵
#ESHLYMPHOMA2026 #ESHCONFERENCES #LYMsm #Lmsm #ESHELEARNING
🎧 soho.click/soho-spotlig... #CARTcell #HemOnc
🎧 soho.click/soho-spotlig... #CARTcell #HemOnc
🎤 Gloria Iacoboni: from transplant-eligible to CAR-T-eligible; CAR-T still favored over bispecifics in R/R LBCL.
#ESHLYMPHOMA2026 #ESHCONFERENCES #LYMsm #Lmsm #ESHELEARNING
🎤 Gloria Iacoboni: from transplant-eligible to CAR-T-eligible; CAR-T still favored over bispecifics in R/R LBCL.
#ESHLYMPHOMA2026 #ESHCONFERENCES #LYMsm #Lmsm #ESHELEARNING
Hub: www.merlintrader.com/adc-therapeu...
Chart: justcharts.merlintrader.com#ADCT
NFA
Hub: www.merlintrader.com/adc-therapeu...
Chart: justcharts.merlintrader.com#ADCT
NFA
Hub: www.merlintrader.com/adc-therapeu...
Chart: justcharts.merlintrader.com#ADCT
NFA
Hub: www.merlintrader.com/adc-therapeu...
Chart: justcharts.merlintrader.com#ADCT
NFA
Bone marrow involvement in diffuse large…
📄 PDF: sjoranm.com/sjoranm/article/download/130/104
#SJORANM #Radiology #NuclearMedicine
Bone marrow involvement in diffuse large…
📄 PDF: sjoranm.com/sjoranm/article/download/130/104
#SJORANM #Radiology #NuclearMedicine
https://www.stocktitan.net/news/CLRB/cellectar-biosciences-reports-case-study-highlighting-complete-1utbiitage9y.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/CLRB/cellectar-biosciences-reports-case-study-highlighting-complete-1utbiitage9y.html?utm_source=stocktitan-bluesky&utm_medium=social
#DLBCL #lymsm #Immunotherapy
#DLBCL #lymsm #Immunotherapy
This review explores how miR-155 influences lymphoma pathogenesis, immune responses and the tumor microenvironment—and its potential as a diagnostic, prognostic or predictive biomarker. #DLBCL #Lymphoma
mdpi.com/2227-9059/12...
This review explores how miR-155 influences lymphoma pathogenesis, immune responses and the tumor microenvironment—and its potential as a diagnostic, prognostic or predictive biomarker. #DLBCL #Lymphoma
mdpi.com/2227-9059/12...
Acta biochimica et biophysica Sinica · Liu et al.
doi.org/10.3724/abbs.2026151
#RNAsky #RNAmods
Acta biochimica et biophysica Sinica · Liu et al.
doi.org/10.3724/abbs.2026151
#RNAsky #RNAmods
A phase 2 study found that dual #HDAC/PI3Kα inhibition with ifupinostat produced clinical responses, alongside substantial hematologic toxicity.
#STTT #OpenAccess: doi.org/10.1038/s413...
A phase 2 study found that dual #HDAC/PI3Kα inhibition with ifupinostat produced clinical responses, alongside substantial hematologic toxicity.
#STTT #OpenAccess: doi.org/10.1038/s413...
初発のびまん性大細胞型B細胞リンパ腫(DLBCL)患者を対象にしたEPCORE DLBCL-2試験で、エプコリタマブとR-CHOP併用療法が無増悪生存期間を有意に改善したことが明らかになりました。
Launches 10/19. Subscribe at soho.click/spotlightpod...
Launches 10/19. Subscribe at soho.click/spotlightpod...
✅ Atezolizumab approved for CRC #crcsm #oncology
🎗️ Tucatinib approved for breast cancer #bcsm
🩸 IberDd hits PFS in myeloma #mmsm #hematology
🔵 Fast track for VIR-5500 in mCRPC #pcsm
🩸 Epcoritamab+R-CHOP hits PFS in DLBCL #lymsm
www.onclive.com/view/the-onc...
✅ Atezolizumab approved for CRC #crcsm #oncology
🎗️ Tucatinib approved for breast cancer #bcsm
🩸 IberDd hits PFS in myeloma #mmsm #hematology
🔵 Fast track for VIR-5500 in mCRPC #pcsm
🩸 Epcoritamab+R-CHOP hits PFS in DLBCL #lymsm
www.onclive.com/view/the-onc...